Pharmacological therapies and drug development targeting SARS-CoV-2 infection

Yizhou Jiang; Limor Rubin; Zhiwei Zhou; Haibo Zhang; Qiaozhu Su; Sheng-Tao Hou; Philip Lazarovici; Wenhua Zheng

doi:10.1016/j.cytogfr.2022.10.003

Pharmacological therapies and drug development targeting SARS-CoV-2 infection

Yizhou Jiang, Limor Rubin, Zhiwei Zhou, Haibo Zhang, Qiaozhu Su, Sheng-Tao Hou^*, Philip Lazarovici, Wenhua Zheng^*

^*Corresponding author for this work

School of Biological Sciences

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

The development of therapies for SARS-CoV-2 infection, based on virus biology and pathology, and of large- and small-scale randomized controlled trials, have brought forward several antiviral and immunomodulatory drugs targeting the disease severity. Casirivimab/Imdevimab monoclonal antibodies and convalescent plasma to prevent virus entry, Remdesivir, Molnupiravir, and Paxlovid nucleotide analogs to prevent viral replication, a variety of repurposed JAK-STAT signaling pathway inhibitors, corticosteroids, and recombinant agonists/antagonists of cytokine and interferons have been found to provide clinical benefits in terms of mortality and hospitalization. However, current treatment options face multiple clinical needs, and therefore, in this review, we provide an update on the challenges of the existing therapeutics and highlight drug development strategies for COVID-19 therapy, based on ongoing clinical trials, meta-analyses, and clinical case reports.

Original language	English
Pages (from-to)	13-24
Journal	Cytokine & Growth Factor Reviews
Volume	68
Early online date	13 Oct 2022
DOIs	https://doi.org/10.1016/j.cytogfr.2022.10.003
Publication status	Published - 01 Dec 2022

Access to Document

10.1016/j.cytogfr.2022.10.003Licence: Unspecified

Cite this

@article{6aa1f7e448084c5a88721ed2ae1e6a76,

title = "Pharmacological therapies and drug development targeting SARS-CoV-2 infection",

abstract = "The development of therapies for SARS-CoV-2 infection, based on virus biology and pathology, and of large- and small-scale randomized controlled trials, have brought forward several antiviral and immunomodulatory drugs targeting the disease severity. Casirivimab/Imdevimab monoclonal antibodies and convalescent plasma to prevent virus entry, Remdesivir, Molnupiravir, and Paxlovid nucleotide analogs to prevent viral replication, a variety of repurposed JAK-STAT signaling pathway inhibitors, corticosteroids, and recombinant agonists/antagonists of cytokine and interferons have been found to provide clinical benefits in terms of mortality and hospitalization. However, current treatment options face multiple clinical needs, and therefore, in this review, we provide an update on the challenges of the existing therapeutics and highlight drug development strategies for COVID-19 therapy, based on ongoing clinical trials, meta-analyses, and clinical case reports.",

author = "Yizhou Jiang and Limor Rubin and Zhiwei Zhou and Haibo Zhang and Qiaozhu Su and Sheng-Tao Hou and Philip Lazarovici and Wenhua Zheng",

year = "2022",

month = dec,

day = "1",

doi = "10.1016/j.cytogfr.2022.10.003",

language = "English",

volume = "68",

pages = "13--24",

journal = "Cytokine & Growth Factor Reviews",

issn = "1359-6101",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Pharmacological therapies and drug development targeting SARS-CoV-2 infection

AU - Jiang, Yizhou

AU - Rubin, Limor

AU - Zhou, Zhiwei

AU - Zhang, Haibo

AU - Su, Qiaozhu

AU - Hou, Sheng-Tao

AU - Lazarovici, Philip

AU - Zheng, Wenhua

PY - 2022/12/1

Y1 - 2022/12/1

N2 - The development of therapies for SARS-CoV-2 infection, based on virus biology and pathology, and of large- and small-scale randomized controlled trials, have brought forward several antiviral and immunomodulatory drugs targeting the disease severity. Casirivimab/Imdevimab monoclonal antibodies and convalescent plasma to prevent virus entry, Remdesivir, Molnupiravir, and Paxlovid nucleotide analogs to prevent viral replication, a variety of repurposed JAK-STAT signaling pathway inhibitors, corticosteroids, and recombinant agonists/antagonists of cytokine and interferons have been found to provide clinical benefits in terms of mortality and hospitalization. However, current treatment options face multiple clinical needs, and therefore, in this review, we provide an update on the challenges of the existing therapeutics and highlight drug development strategies for COVID-19 therapy, based on ongoing clinical trials, meta-analyses, and clinical case reports.

AB - The development of therapies for SARS-CoV-2 infection, based on virus biology and pathology, and of large- and small-scale randomized controlled trials, have brought forward several antiviral and immunomodulatory drugs targeting the disease severity. Casirivimab/Imdevimab monoclonal antibodies and convalescent plasma to prevent virus entry, Remdesivir, Molnupiravir, and Paxlovid nucleotide analogs to prevent viral replication, a variety of repurposed JAK-STAT signaling pathway inhibitors, corticosteroids, and recombinant agonists/antagonists of cytokine and interferons have been found to provide clinical benefits in terms of mortality and hospitalization. However, current treatment options face multiple clinical needs, and therefore, in this review, we provide an update on the challenges of the existing therapeutics and highlight drug development strategies for COVID-19 therapy, based on ongoing clinical trials, meta-analyses, and clinical case reports.

U2 - 10.1016/j.cytogfr.2022.10.003

DO - 10.1016/j.cytogfr.2022.10.003

M3 - Article

SN - 1359-6101

VL - 68

SP - 13

EP - 24

JO - Cytokine & Growth Factor Reviews

JF - Cytokine & Growth Factor Reviews

ER -

Pharmacological therapies and drug development targeting SARS-CoV-2 infection

Abstract

Access to Document

Fingerprint

Cite this